Skip to main content
Clinical Trials/CTRI/2024/05/066914
CTRI/2024/05/066914
Not yet recruiting
Phase 2

Comparative efficacy of combined pharmacotherapy (Ibuprofen + Paracetamol) versus monotherapy (Ibuprofen) in the treatment of hemodynamically significant PDA - A Double Blind Randomised Controlled Trial at a level III NICU in LMIC - NI

Govind Choudhary0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: Q250- Patent ductus arteriosus
Sponsor
Govind Choudhary
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Govind Choudhary

Eligibility Criteria

Inclusion Criteria

  • 1\. Preterm neonates less than 32 week admitted in the NICU with hemodynamically significant PDA between 12 and 72 hours of life.
  • 2\. Written Informed parental or guardian consent obtained

Exclusion Criteria

  • 1\. Major lethal congenital malformations
  • 2\.Echocardiographic evidence of pulmonary hypertension.
  • 3\. IVH grade III or more
  • 4\. Platelet count less than 50,000/mm3

Outcomes

Primary Outcomes

Not specified

Similar Trials